Group 1 - The core point of the article is the establishment of Jiahe Zhijian (Henan) Technology Co., Ltd. with a registered capital of 100 million yuan, focusing on the development of intelligent robots and artificial intelligence software [1] - The company is co-owned by Beijing Xingdong Jiyuan Technology Co., Ltd., Zhengzhou Airport Technology Capital Group Co., Ltd., Zhengzhou Hengjian Lizhi Enterprise Management Partnership (Limited Partnership), and Jiahe Meikang (688246) [1] - The business scope includes research and development of intelligent robots, development of basic software for artificial intelligence, and development of theoretical and algorithmic software for artificial intelligence [1]

人民财讯12月11日电，企查查APP显示，近日，嘉和智健(河南)科技有限公司成立，注册资本1亿元，经 营范围包含：智能机器人的研发；人工智能基础软件开发；人工智能理论与算法软件开发；人工智能应 用软件开发等。企查查股权穿透显示，该公司由嘉和美康、北京星动纪元科技有限公司等共同持股。 ...

天眼查App显示，12月9日，嘉和智健（河南）科技有限公司成立，法定代表人为边卫斌，注册资本1亿 人民币，经营范围包括智能机器人的研发、人工智能基础软件开发、人工智能理论与算法软件开发等， 由北京星动纪元科技有限公司、郑州航空港科技资本集团有限公司、郑州亨健利智企业管理合伙企业 （有限合伙）、嘉和美康（688246）共同持股。 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-072 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 特此公告。 嘉和美康（北京）科技股份有限公司董事会 2025年12月3日 崔力先生，毕业于北京大学，获硕士学位，中国注册会计师非执业会员、保荐代表人。于2015年加入华 泰联合证券，主要参与了八马茶业港股上市项目、居然之家借壳上市项目、中公教育借壳上市项目、成 商集团借壳上市项目、中材国际收购合肥院项目、美丽田园收购奈瑞儿项目、茂业商业现金购买维多利 项目、新希望收购本香农业项目、众信旅游收购竹园国旅项目。崔力先生还参与多家拟上市公司的改制 辅导、多个资本运作项目的方案论证和设计工作，资本市场运作经验丰富。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于近日收到华泰联合证券有限责任公司（以下 简称"华泰联合证券"）出具的《华泰联合证券有限责任公司关于更换嘉和美康（北京）科技股份有限公 司首次公开发行股票持续督导保荐代表人的函》。 华泰联合证券作为公司首次公开发行股票的保荐机构，原指定保荐代表人孔祥熙 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-072 附件：崔力个人简历 嘉和美康（北京）科技股份有限公司董事会 2025 年 12 月 3 日 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于近日收到华泰 联合证券有限责任公司（以下简称"华泰联合证券"）出具的《华泰联合证券有 限责任公司关于更换嘉和美康（北京）科技股份有限公司首次公开发行股票持续 督导保荐代表人的函》。 华泰联合证券作为公司首次公开发行股票的保荐机构，原指定保荐代表人孔 祥熙先生、王琛女士负责保荐工作及持续督导工作，法定持续督导期至 2024 年 12 月 31 日止。截至目前，由于公司首次公开发行股份募集资金尚未使用完毕， 持续督导期延续。 现孔祥熙先生因工作变动不再继续负责公司的持续督导工作。为保证持续督 导工作的有序进行，华泰联合证券委派崔力先生接替孔祥熙先生履行公司持续督 导职责。本次变更后，公司首次公开发行股票的持续督导保荐代表人为王琛女士 和崔力先生。 公司对孔祥熙先生在担任保荐代表人期间所做出的贡献表示感谢！ 特此公告。 嘉和美康（北京）科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及 ...

Core Viewpoint - The Shanghai Stock Exchange has criticized Jiahe Meikang (Beijing) Technology Co., Ltd. for accounting errors in its financial reports for 2022 and 2023, which significantly impacted its reported profits and raised concerns about the accuracy of its financial disclosures [1][2][3] Group 1: Financial Reporting Issues - Jiahe Meikang disclosed accounting errors that led to a profit reduction of 4.05 million yuan for 2022, representing a 14.81% decrease, and a net profit reduction of 3.45 million yuan, a decrease of 8.46% [1] - For 2023, the company reported a profit reduction of 11.35 million yuan, which is a 169.95% decrease, and a net profit reduction of 10.21 million yuan, a decrease of 50.35% [1][2] Group 2: Regulatory Violations - The inaccuracies in financial disclosures violated the rules set forth in the "General Provisions of Financial Reports" and the "Shanghai Stock Exchange Sci-Tech Innovation Board Stock Listing Rules" [2] - The then Chairman and General Manager, Xia Jun, and the then Financial Officer, Ren Yong, were held responsible for the company's violations due to their failure to fulfill their duties [2] Group 3: Company Background and Financial Performance - Jiahe Meikang was listed on the Shanghai Stock Exchange on December 14, 2021, with an initial offering price of 39.50 yuan per share, raising a total of 1.362 billion yuan [3] - The company reported a revenue of 592 million yuan in 2024, a year-on-year decrease of 14.85%, and a net loss of 256 million yuan [4] - In the first three quarters of the current year, the company achieved a revenue of 330 million yuan, a decrease of 30.67%, with a net loss of 174 million yuan [4]

Core Viewpoint - Jiahe Meikang (Beijing) Technology Co., Ltd. has faced disciplinary action from the Shanghai Stock Exchange due to accounting errors in its financial reports for 2022 and 2023, leading to significant adjustments in reported profits and net income [2][3] Financial Reporting Issues - The company disclosed multiple announcements on April 30, 2025, correcting accounting errors related to cost recognition and insufficient inventory impairment provisions for 2022 and 2023 [2] - For 2022, total profit was reduced by 4.0544 million yuan, representing a 14.81% decrease, while net profit was adjusted down by 3.4463 million yuan, a decrease of 8.46% [2] - For 2023, total profit was reduced by 11.3478 million yuan, a 169.95% increase in losses, and net profit was adjusted down by 10.213 million yuan, a decrease of 50.35% [2] Disciplinary Actions - The Shanghai Stock Exchange criticized the company and its key executives for failing to ensure accurate financial disclosures, impacting investors' rights [3] - The disciplinary committee found that the company's prior accounting errors were significant and warranted criticism, despite the company's claims of corrective measures [3] Company Performance and Market Position - Jiahe Meikang is a leading provider of medical information technology products and services, holding a 15.0% market share in the electronic medical record system market as of 2024, marking its 11th consecutive year at the top [4] - However, the company has experienced declining revenues, with figures of 717 million yuan in 2022, 695 million yuan in 2023, and a projected 330 million yuan in 2024, reflecting year-on-year changes of -9.97%, -3.04%, -14.85%, and -30.67% respectively [4] - Net profits have also declined significantly, with losses reported at 25.6 million yuan in 2023 and 17.4 million yuan in the first three quarters of 2025 [4] Industry Challenges - The company cited a complex industry environment, with delayed demand from hospital clients, prolonged bidding processes, and increased project implementation costs as factors contributing to revenue decline and losses [5]

根据纪律处分决定，上交所对嘉和美康及时任董事长兼总经理夏军、时任财务负责人任勇予以通报批 评，并将通报中国证监会，记入证券期货市场诚信档案数据库。同时要求公司及董监高采取有效措施整 改，排查合规隐患，提高信息披露和规范运作水平，并在收到决定书后一个月内提交经全体董监高签字 确认的整改报告。 #嘉和美康连续两年报高利润被通报批评#【连续两年"报高"利润，事隔一年才更正，A股公司董事长被 通报批评，并记入诚信档案数据库！此前请求减轻处分被拒】11月28日，嘉和美康公开了一份来自上海 证券交易所（简称上交所）的纪律处分决定书。 记者注意到，针对上述违规事项，嘉和美康公司及有关责任人曾请求减轻处分，但被上交所以所涉时间 跨度长、涉及重要会计科目、调整金额及占比较大等理由拒绝。而且，这家号称"连续11年荣膺我国电 子病历行业市占率第一"的企业，今年上半年的净亏损同比扩大超300%。（每经） 公告显示，公司在今年4月发布了关于前期会计差错更正及定期报告更正的公告，调低了2022年、2023 年的利润总额和净利润，其中2022年的净利润调减344.63万元，占更正前金额的8.46%；2023年的净利 润调减1021.3万元 ...

Core Viewpoint - Jiahe Meikang has faced disciplinary action from the Shanghai Stock Exchange due to significant accounting errors in its financial reports for 2022 and 2023, leading to substantial profit reductions and a worsening financial situation in 2024 [1][2][3]. Financial Reporting Issues - The company announced corrections to its financial statements, reducing the 2022 net profit by 3.4463 million yuan, which is 8.46% of the original amount, and the 2023 net profit by 10.213 million yuan, which is 50.35% of the original amount [1][2]. - The corrections were attributed to accounting errors, including misreporting of costs and insufficient provisions for inventory depreciation [2]. Disciplinary Actions - The Shanghai Stock Exchange criticized the company's former chairman and financial officer, requiring the company to implement corrective measures and submit a report within one month [3][4]. Financial Performance - Jiahe Meikang reported a significant decline in net profit from 2021 to 2024, with a projected net profit of -256 million yuan in 2024, reflecting a year-on-year decline of 893.31% [5]. - The company experienced a 27.22% decrease in revenue in the first half of the year, with a net loss of 116 million yuan, compared to a loss of 27.47 million yuan in the same period last year, marking a 323.29% increase in losses [6]. Market Position - Despite being recognized as the leading provider in the electronic medical record market in China for eleven consecutive years, the company's financial struggles contrast sharply with its market position [5].

Core Viewpoint - The company Jiahe Meikang has faced significant financial corrections and disciplinary actions from the Shanghai Stock Exchange due to accounting errors that have led to substantial reductions in reported profits for 2022 and 2023 [2][3][4]. Financial Corrections - In April, Jiahe Meikang announced corrections to its financial reports, reducing the net profit for 2022 by 3.4463 million yuan, which is 8.46% of the original amount, and for 2023 by 10.213 million yuan, which is 50.35% of the original amount [2][3]. - The total profit adjustments for 2022 amounted to 4.0544 million yuan (14.81% reduction) and for 2023, 11.3478 million yuan (169.95% increase in losses) [3]. Disciplinary Actions - The Shanghai Stock Exchange issued a disciplinary notice, criticizing the company's former chairman and financial officer, and requiring the company to submit a rectification report within one month [4]. - The company has been instructed to improve its compliance and information disclosure practices [4]. Financial Performance - Jiahe Meikang reported a significant increase in losses, with a net profit of -256 million yuan for 2024, reflecting a year-on-year decline of 893.31% [5]. - The company’s revenue for the first half of the year was 219 million yuan, a decrease of 27.22% year-on-year, with net losses expanding to -116 million yuan, compared to -27.47 million yuan in the same period last year, marking a 323.29% increase in losses [6]. Market Position - Despite being recognized as the leading company in the electronic medical record market in China for eleven consecutive years, Jiahe Meikang's recent financial struggles contrast sharply with its market position [5]. - The company serves over 650 tertiary hospitals, accounting for more than one-third of such hospitals in the country, indicating its significant market presence [5].